Podcast Music Movie Game Book
  1. 🎧Podcast
  2. 🎧U.S. Food and Drug Administration, Center for Drug Evaluation and Research
  3. FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for high-risk early-stage triple-negative breast cancer

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for high-risk early-stage triple-negative breast cancer

Release Date:

Listen to a soundcast of the July 26, 2021 FDA approval of Keytruda (pembrolizumab) for high-risk early-stage triple-negative breast cancer

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for high-risk early-stage triple-negative breast cancer
Title
FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for high-risk early-stage triple-negative breast cancer
Copyright
Release Date

flashback